mva-np
Vaccineexperimental
Clinical trial activity
9 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2008 (NCT00942071)
Timeline
Indications
Mechanism of action
- Influenza A virusImmunity, active
Influenza A virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- mva-np
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03883113 | Phase 2 | Apr 2, 2019 | Barinthus Biopharmaceuticals, SGS Life Sciences |
| NCT03880474 | Phase 2 | Mar 18, 2019 | Barinthus Biopharmaceuticals, Clinical Network Services, Paratus Clinical |
| NCT03300362 | Phase 2 | Oct 13, 2017 | Barinthus Biopharmaceuticals, University of Oxford, University of Sussex |
| NCT03277456 | Early Phase 1 (Phase 1) | Sep 18, 2017 | Barinthus Biopharmaceuticals, University of Oxford |
| NCT02014168 | Phase 1 | Jan 1, 2014 | University of Oxford |
| NCT01818362 | Phase 1 | Apr 1, 2013 | University of Oxford |
| NCT01465035 | Phase 1 | Oct 1, 2011 | University of Oxford |
| NCT00993083 | Phase 2 | Jun 1, 2009 | University of Oxford, Wellcome Trust |
| NCT00942071 | Phase 1 | Aug 1, 2008 | University of Oxford, Wellcome Trust |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Oxford | Academic/Hospital | 7 | 5 | 2 | 2008 |
| Barinthus Biopharmaceuticals | For profit | 4 | 4 | 2 | 2017 |
| Wellcome Trust | Academic/Hospital | 2 | 0 | 2 | 2008 |
| Clinical Network Services | For profit | 1 | 0 | 1 | 2019 |
| Paratus Clinical | For profit | 1 | 0 | 1 | 2019 |
| SGS Life Sciences | For profit | 1 | 0 | 1 | 2019 |
| University of Sussex | Academic/Hospital | 1 | 0 | 1 | 2017 |
7 organizations
Page 1 / 1